474 assets in Plasma Cell Myeloma

Therapeutic assets addressing Plasma Cell Myeloma, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Atezolizumab Plasma Cell Myeloma	Genentech, Inc.	P2	CCC (55)
Azacitidine Plasma Cell Myeloma	Sumitomo Pharma America, Inc.	P2	CCC (55)
Clarithromycin Plasma Cell Myeloma	Weill Medical College of Cornell University	P3	CCC (55)
Vemurafenib Plasma Cell Myeloma	Cancer Research UK	P2/3	CCC (55)
Abemaciclib Plasma Cell Myeloma	OHSU Knight Cancer Institute	P2	CCC (54)
Amoxicillin Plasma Cell Myeloma	Monash University	P2/3	CCC (54)
Anti-Bcma Car-Nk Cells Plasma Cell Myeloma	Shahid Beheshti University of Medical Sciences	P1/2	CCC (54)
Anti-Bcma Car T Cells Plasma Cell Myeloma	Hebei Senlang Biotechnology Inc., Ltd.	P1/2	CCC (54)
Clavulanic Acid Plasma Cell Myeloma	Monash University	P2/3	CCC (54)
Clofarabine Plasma Cell Myeloma	M.D. Anderson Cancer Center	P2	CCC (54)
Cobimetinib Plasma Cell Myeloma	Cancer Research UK	P2/3	CCC (54)
ct103a Plasma Cell Myeloma	Chunrui Li	P1/2	CCC (54)
Darzalex Faspro Plasma Cell Myeloma	Shanghai Henlius Biotech	P3	CCC (54)
Fenofibrate Plasma Cell Myeloma	Tanta University	P4	CCC (54)
hlx15 Plasma Cell Myeloma	Shanghai Henlius Biotech	P3	CCC (54)
Human Normal Immunoglobulin (Ivig) Plasma Cell Myeloma	Takeda	P3	CCC (54)
ibi3003 Plasma Cell Myeloma	Innovent Biologics (Suzhou) Co. Ltd.	P3	CCC (54)
Ipilimumab Plasma Cell Myeloma	OHSU Knight Cancer Institute	P2	CCC (54)
Lispro-Ph20 Component Rhuph20 Plasma Cell Myeloma	SWOG Cancer Research Network	P3	CCC (54)
Ramantamig Plasma Cell Myeloma	Janssen Research & Development, LLC	P3	CCC (54)
Rivaroxaban Plasma Cell Myeloma	Union Hospital, Tongji Medical College, Huazhong University of Science and Technology	P3	CCC (54)
Sctc21C Plasma Cell Myeloma	Sinocelltech Ltd.	P3	CCC (54)
tqb2934 Plasma Cell Myeloma	Chia Tai Tianqing Pharmaceutical Group Co., Ltd.	P3	CCC (54)
Tretinoin Plasma Cell Myeloma	The Methodist Hospital Research Institute	P2	CCC (54)
Anti-Bcma Car-T Plasma Cell Myeloma	Institute of Hematology & Blood Diseases Hospital, China	P2	CCC (53)
Bcma-Gprc5D Car-T Cells Plasma Cell Myeloma	Donghua Zhang	P2	CCC (53)
Denosumab Plasma Cell Myeloma	RenJi Hospital	P3	CCC (53)
Treosulfan Plasma Cell Myeloma	Insel Gruppe AG, University Hospital Bern	P2	CCC (53)
Anti-Bcma/Gprc5D Bispecific Car-T Plasma Cell Myeloma	Institute of Hematology & Blood Diseases Hospital, China	P2	CCC (52)
Anti-Gprc5D Car-T Cells Plasma Cell Myeloma	XuYan	P1/2	CCC (52)
Autologous Peripheral Blood Mononuclear Cell (Pbmc)-Derived T Lymphocytes Transduced Ex Vivo With A Non-Replicating, Self-Inactivating (Sin) Lentiviral Vector Encodinga Chimeric Antigen Receptor (Car) Targeting Two Epitopes Of The Human B Cell Maturation Antigen (Bcma) Under The Control Of A Human Elongation Factor 1 Alpha (Ef1.Alpha.) Promoter The Coding Sequence Comprises A Human Cd8 Alpha Signal Peptide (Cd8.Alpha. Sp), A Bcma Targeting Domain Consisting Of Two Variable Heavy Chain-Only Antibodies (Vhh1 And Vhh2) Targeting Two Distinct Bcma Epitopes, A Human Cd8 Alpha Hinge And Transmembrane Domain (Cd8.Alpha. Hinge + Tm), A Human Cd137 Cytoplasmic Domain (4-1Bb) And A Human Cd3 Zeta Cytoplasmic Domain (Cd3.Zeta.). The Vector Genome Contains A Chimeric Rous Sarcoma Virus (Rsv)/Truncated 5'Ltr And A Self-Inactivating 3'Ltr-Sin (.Delta.-U3) Plasma Cell Myeloma	Janssen Research & Development, LLC	P2	CCC (52)
Bcma-Cart Cells Plasma Cell Myeloma	Institute of Hematology & Blood Diseases Hospital, China	P1/2	CCC (52)
Crizotinib Plasma Cell Myeloma	Canadian Cancer Trials Group	P2	CCC (52)
Dc/Mm Fusion Vaccine Plasma Cell Myeloma	David Avigan	P2	CCC (52)
Famotidine Plasma Cell Myeloma	Emory University	P4	CCC (52)
Forimtamig Plasma Cell Myeloma	Hoffmann-La Roche	P1/2	CCC (52)
Gsk-2636771 Plasma Cell Myeloma	National Cancer Institute (NCI)	P2	CCC (52)
Isatuximab Irfc Plasma Cell Myeloma	Arbeitsgemeinschaft medikamentoese Tumortherapie	P2	CCC (52)
Letermovir Plasma Cell Myeloma	Seoul National University Hospital	P2	CCC (52)
Marizomib Plasma Cell Myeloma	Dana-Farber Cancer Institute	P2	CCC (52)
Nadravaleucel Plasma Cell Myeloma	David Wald	P1/2	CCC (52)
Nepenthe Plasma Cell Myeloma	University Hospital Heidelberg	P3	CCC (52)
Palbociclib Plasma Cell Myeloma	OHSU Knight Cancer Institute	P2	CCC (52)
Pentaisomaltose Plasma Cell Myeloma	Pharmacosmos A/S	P4	CCC (52)
Recombinant Human Granulocyte Colony-Stimulating Factor Plasma Cell Myeloma	Emory University	P4	CCC (52)
Synthetic Mva-Based Sars-Cov-2 Vaccine Geo-Cm04S1 Plasma Cell Myeloma	GeoVax, Inc.	P2	CCC (52)
Trastuzumab Plasma Cell Myeloma	OHSU Knight Cancer Institute	P2	CCC (52)
Dabrafenib Plasma Cell Myeloma	Cancer Research UK	P2/3	CCC (51)
Flavone, 3,3',4',5,7-Pentahydroxy- Plasma Cell Myeloma	Mayo Clinic	P2	CCC (51)
Immunoglobulin G1-Lambda2, Anti-(Severe Acute Respiratory Syndrome (Human) Coronavirus 2 (Sars-Cov-2) Spike (S) Glycoprotein, Receptor Binding Domain (Rbd)), Homo Sapiens Monoclonal Antibod Plasma Cell Myeloma	Imperial College Healthcare NHS Trust	P2	CCC (51)

Showing 101 to 150 of 474 assets

PreviousPage 3 of 10Next